Vyome Biosciences to Present Data on Breakthrough Molecular Replacement Therapy (MRT™) Targeting Fungal Infections at ASM Microbe 2016 Conference, Boston

NEW DELHI

Vyome Biosciences, a clinical stage biopharmaceutical company pioneering innovation driven dermatology R&D of novel platform technologies and drugs that target the critical unmet needs of antimicrobial resistance of opportunistic pathogens of the skin, announced today that research findings for the Company’s advanced anti-fungal platform technology, Molecular Replacement Therapy (MRT^™), will be presented through poster at American Society of Microbiology (ASM) Microbe 2016 Conference, taking place in Boston, MA, on June 16-20, 2016.

Trichophyton spp. are dermatophyte fungi that invade and grow in the keratin of skin, hair and nails, and are responsible for various skin infections like ring worm, athlete’s foot etc. Depending on the site of the infection, different topical antimycotics show varied degree of therapeutic benefits. In recent years, there have also been reports of drug resistance in dermatophytes that further aggravate the clinical manifestation. In pursuit of addressing these unmet clinical needs, Vyome has developed a platform technology, MRT^™, which not only imparts enhanced fungal killing ability to a known agent, but also allows its higher retention in the skin. Therefore, a two-pronged effect, an immediate impact of the formulation on fungus residing in the upper layers of the skin, followed by a long term sustained effect of higher retained amount of actives on fungus residing in deeper layers of the skin, becomes evident.

“There is an urgent need for novel anti-fungal platform technologies that can overcome the rising unmet need of resistance in existing treatment classes like azoles. We believe that the promising data on Vyome’s innovative anti-fungal technology platform, MRT^™, will provide a strong base for the continued development of MRT^™ as a novel platform for potentiating known anti-fungals for the treatment of fungal infections including Tinea infections,” said N. Venkat, Co-Founder & CEO, Vyome Biosciences.

About Vyome Biosciences

Vyome Biosciences is a clinical stage dermatology based biopharmaceutical company, which has novel platforms technologies and a deep pipeline of novel drugs for antibiotic resistant acne, other opportunistic pathogens and antifungal agents. Vyome has put together a team of scientific and management experts from India and USA to deliver company’s growth plans. Vyome is co-founded by Shiladitya Sengupta, Venkateswarlu Nelabhotla (N. Venkat), Rajesh Gokhale and Rajeev Mantri.

Vyome’s VB 1953, a novel drug targeting antibiotic resistant acne, had its IND (Investigational New Drug) application accepted by the US FDA in Jan 2016. Vyome also has a deep pipeline of NCEs unique in their ability to resist the development of resistance based on its patented Dual Action Rational Therapeutics (DART^™) technology, which are in pre-clinical stage. In addition, Vyome has clinically proven products to treat scalp & skin seborrheic dermatitis, for which Vyome is currently pursuing partnering discussion globally.

For additional information about Vyome, please visit: www.vyome.in or follow on Twitter @VyomeBio

View source version on businesswire.com: http://www.businesswire.com/news/home/20160614006213/en/